Recombinant Anti-SRSF3 antibody [EPR16976] (ab198291)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR16976] to SRSF3
- Suitable for: WB, IHC-P, ICC/IF, Flow Cyt (Intra)
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-SRSF3 antibody [EPR16976]
See all SRSF3 primary antibodies -
Description
Rabbit monoclonal [EPR16976] to SRSF3 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-P, ICC/IF, Flow Cyt (Intra)more details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Jurkat, HepG2, C6, RAW 264.7, PC-12, NIH/3T3 and K562 whole cell lysates. Mouse and Rat brain lysates. IHC-P: Human cervix carcinoma and Human cerebral cortex tissue. Mouse liver tissue. ICC/IF: HeLa, and PC-12 cells. Flow Cyt (intra): Jurkat cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR16976 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab198291 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (2) |
1/1000. Detects a band of approximately 19 kDa (predicted molecular weight: 19 kDa).
|
IHC-P |
1/250. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
|
ICC/IF | (2) |
1/500.
|
Flow Cyt (Intra) |
1/250.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Notes |
---|
WB
1/1000. Detects a band of approximately 19 kDa (predicted molecular weight: 19 kDa). |
IHC-P
1/250. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
ICC/IF
1/500. |
Flow Cyt (Intra)
1/250. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Target
-
Function
May be involved in RNA processing in relation with cellular proliferation and/or maturation. -
Sequence similarities
Belongs to the splicing factor SR family.
Contains 1 RRM (RNA recognition motif) domain. -
Post-translational
modificationsExtensively phosphorylated on serine residues in the RS domain. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 6428 Human
- Entrez Gene: 20383 Mouse
- Entrez Gene: 361814 Rat
- Omim: 603364 Human
- SwissProt: P84103 Human
- SwissProt: P84104 Mouse
- Unigene: 405144 Human
- Unigene: 6787 Mouse
-
Alternative names
- arginine/serine-rich 3 antibody
- Pre mRNA splicing factor SRP20 antibody
- Pre-mRNA-splicing factor SRP20 antibody
see all
Images
-
All lanes : Anti-SRSF3 antibody [EPR16976] (ab198291) at 1/5000 dilution
Lane 1 : Jurkat (Human T cell leukemia cells from peripheral blood) whole cell lysate
Lane 2 : HepG2 (Human liver hepatocellular carcinoma) whole cell lysate
Lane 3 : K562 (Human chronic myelogenous leukemia cells from bone marrow) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 19 kDa
Observed band size: 19 kDaBlocking/dilution buffer: 5% NFDM/TBST.
-
Immunocytochemistry/Immunofluorescence analysis of PC-12 (Rat adrenal gland pheochromocytoma cell line) labelling SRSF3 with purified ab198291 at 1/500. Cells were fixed with 4% PFA and permeabilized with 0.1% triton X-100. ab150077 Goat anti rabbit IgG (Alexa Fluor® 488) at 1/1000 was used as the secondary antibody. Nuclei were counterstained with DAPI. PBS was used instead of the primary antibody as the negative control.
-
All lanes : Anti-SRSF3 antibody [EPR16976] (ab198291) at 1/1000 dilution
Lane 1 : Mouse brain lysate
Lane 2 : Rat brain lysate
Lane 3 : C6 (Rat glial tumor) whole cell lysate
Lane 4 : RAW 264.7(Mouse macrophage cells transformed with Abelson murine leukemia virus) whole cell lysate
Lane 5 : PC-12 (Rat adrenal gland pheochromocytoma) whole cell lysate
Lane 6 : NIH/3T3 (Mouse embryo fibroblast cells) whole cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 19 kDa
Observed band size: 19 kDaBlocking/dilution buffer: 5% NFDM/TBST.
-
Immunohistochemical analysis of paraffin-embedded Human cervix carcinoma tissue labeling SRSF3 with ab198291 at 1/500 dilution followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution. Nuclear staining on Human cervix carcinoma tissue is observed. Counter stained with Hematoxylin.
Negative control: Used PBS instead of primary ab.Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin-embedded Human cerebral cortex tissue labeling SRSF3 with ab198291 at 1/500 dilution followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution. Nuclear and weakly cytoplasm staining on Human cerebral cortex tissue is observed. Counter stained with Hematoxylin.
Negative control: Used PBS instead of primary ab.Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin-embedded Mouse liver tissue labeling SRSF3 with ab198291 at 1/500 dilution followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution. Nuclear and weakly cytoplasm staining on mouse liver tissue is observed. Counter stained with Hematoxylin.
Negative control: Used PBS instead of primary ab.Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Intracellular flow cytometric analysis of 2% paraformaldehyde-fixed Jurkat (Human T Cell Leukemia cells from peripheral blood)labeling SRSF3with ab198291 at 1/440 dilution (red) compared with a Rabbit monoclonal IgG isotype control (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody; blue). Goat anti rabbit IgG (FITC) at 1/150 dilution was used as the secondary antibody.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (15)
ab198291 has been referenced in 15 publications.
- Chen Y et al. SRSF3 Promotes Angiogenesis in Colorectal Cancer by Splicing SRF. Front Oncol 12:810610 (2022). PubMed: 35198444
- Li Z et al. SRSF3 Expression Serves as a Potential Biomarker for Prognostic and Immune Response in Pan-Cancer. Front Oncol 12:808530 (2022). PubMed: 35494088
- Guo L et al. TDP43 promotes stemness of breast cancer stem cells through CD44 variant splicing isoforms. Cell Death Dis 13:428 (2022). PubMed: 35504883
- Wang ZW et al. SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine. Cell Rep 39:110813 (2022). PubMed: 35545048
- Krasny L et al. Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis. Cancers (Basel) 14:N/A (2022). PubMed: 35740573